Pharmacogenetics and Age-Related Macular Degeneration

Table 3

Pharmacogenetics of antivascular endothelial growth factor therapy.

Treatment	Genes	Result
Bevacizumab	CFH and ARMS2	CFH CC associated with worse visual outcomes; no association with ARMS2 [65]
Bevacizumab	CFH	CFH CC associated with worse visual outcomes [66]
Ranibizumab	CFH	CFH CC associated with more injections performed [67]
Ranibizumab	CFH and ARMS2	ARMS2 TT associated with worse visual outcomes; CFH CC associated with relatively worse visual outcomes [68]
Ranibizumab	Multiple	CFH CC associated with poor treatment response; combination heterozygotes at CFH and FZD4 associated with more favorable outcomes; no association with CFB, HTRA1, ARMS2, VEGFA, KDR, and LRP5 [69]
Ranibizumab	CFH, HTRA1, and VEGF	CFH TC associated with better visual outcomes; no association with number of injections with any gene [70]
Bevacizumab and/or ranibizumab	APOE	APOE ε4 associated with better treatment outcomes [71]